NCT01862965View on ClinicalTrials.gov

Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 6, 2013

Primary Completion Date

February 7, 2018

Study Completion Date

March 31, 2019

Conditions
Chronic Graft-versus-host Disease
Interventions
DRUG

PredEver

Firstline treatment with prednisone and Everolimus

Trial Locations (6)

20246

Universitätsklinikum Hamburg-Eppendorf, Hamburg

55101

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

65191

Deutsche Klinik fuer Diagnostik GmbH, Wiesbaden

89081

Universitätsklinikum Ulm, Ulm

93053

Klinikum der Universität Regensburg, Regensburg

07743

Universitätsklinikum Jena, Jena

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

Crolll Gmbh

OTHER

lead

Universitätsklinikum Hamburg-Eppendorf

OTHER

NCT01862965 - Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus | Biotech Hunter | Biotech Hunter